Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
MENLO PARK, Calif., Aug. 02, 2017 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its second quarter ended June 30, 2017.
Product, service and other revenue for the second quarter of 2017 increased by 17% to $20.1 million, compared to $17.2 million for the second quarter of 2016. Total revenue for the second quarter of 2017 was $20.1 million, compared to $20.7 million for the second quarter of 2016. Total revenue for the second quarter of 2016 included $3.6 million of contractual revenue, whereas the second quarter of 2017 included no contractual revenue.
Gross profit for the second quarter of 2017 was $8.0 million, resulting in a gross margin of 39.9%. Gross profit for the second quarter of 2016 was $10.6 million, resulting in a gross margin of 51.3%. This included $3.6 million of contractual revenue at 100% gross margin. Excluding this contractual revenue and related margin, adjusted gross margin for the second quarter of 2016 would have been 41.1%. Adjusted gross margin is not meant to be considered in isolation or as a substitute for gross margin. Adjusted gross margin is subject to limitations and should be read only in conjunction with the Company’s condensed consolidated financial statements prepared in accordance with GAAP.
Operating expenses for the second quarter of 2017 totaled $32.4 million, compared to $28.7 million for the second quarter of 2016. Operating expenses for the second quarter of 2017 and 2016 included non-cash stock-based compensation of $4.4 million and $4.5 million, respectively.
Net loss for the second quarter of 2017 was $25.5 million, compared to $18.5 million for the second quarter of 2016.
Cash, cash equivalents and investments, excluding restricted cash, at June 30, 2017 totaled $102.6 million, compared to $72.0 million at December 31, 2016.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its second quarter 2017 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using an Audience Passcode of 6231-3559. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/ .
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products, future uses, quality or performance of, or benefits of using, products or technologies and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
| Pacific Biosciences of California, Inc. | |||||||||||||||||||||||||
| Unaudited Condensed Consolidated Statement of Operations | |||||||||||||||||||||||||
| (amounts in thousands, except per share amounts) | |||||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||||
| Product revenue | $ | 16,548 | $ | 13,587 | $ | 37,842 | $ | 25,966 | |||||||||||||||||
| Service and other revenue | 3,525 | 3,564 | 7,146 | 6,716 | |||||||||||||||||||||
| Contractual revenue | — | 3,596 | — | 7,192 | |||||||||||||||||||||
| Total revenue | 20,073 | 20,747 | 44,988 | 39,874 | |||||||||||||||||||||
| Cost of Revenue: | |||||||||||||||||||||||||
| Cost of product revenue | 8,155 | 7,115 | 19,517 | 13,995 | |||||||||||||||||||||
| Cost of service and other revenue | 3,917 | 2,988 | 8,533 | 5,731 | |||||||||||||||||||||
| Total cost of revenue | 12,072 | 10,103 | 28,050 | 19,726 | |||||||||||||||||||||
| Gross profit | 8,001 | 10,644 | 16,938 | 20,148 | |||||||||||||||||||||
| Operating Expense: | |||||||||||||||||||||||||
| Research and development | 16,883 | 17,522 | 33,854 | 33,883 | |||||||||||||||||||||
| Sales, general and administrative | 15,505 | 11,192 | 30,770 | 22,900 | |||||||||||||||||||||
| Total operating expense | 32,388 | 28,714 | 64,624 | 56,783 | |||||||||||||||||||||
| Operating loss | (24,387 | ) | (18,070 | ) | (47,686 | ) | (36,635 | ) | |||||||||||||||||
| Interest expense | (826 | ) | (795 | ) | (1,664 | ) | (1,574 | ) | |||||||||||||||||
| Other income (expense), net | (326 | ) | 366 | (56 | ) | 358 | |||||||||||||||||||
| Net loss | $ | (25,539 | ) | $ | (18,499 | ) | $ | (49,406 | ) | $ | (37,851 | ) | |||||||||||||
| Basic and diluted net loss per share | $ | (0.26 | ) | $ | (0.21 | ) | $ | (0.52 | ) | $ | (0.44 | ) | |||||||||||||
| Shares used in computing basic and diluted net loss per share | 97,360 | 88,148 | 95,177 | 85,876 | |||||||||||||||||||||
| Pacific Biosciences of California, Inc. | |||||
| Unaudited Condensed Consolidated Balance Sheets | |||||
| (amounts in thousands) | |||||
| June 31, | December 31, | ||||
| 2017 | 2016 | ||||
| Assets | |||||
| Cash and investments | $ | 102,596 | $ | 71,978 | |
| Accounts receivable | 9,525 | 11,421 | |||
| Inventory | 17,266 | 15,634 | |||
| Prepaid and other current assets | 3,545 | 9,978 | |||
| Property and equipment | 40,289 | 14,560 | |||
| Long-term restricted cash | 4,500 | 4,500 | |||
| Other long-term Assets | 184 | 9,813 | |||
| Total Assets | $ | 177,905 | $ | 137,884 | |
| Liabilities and Stockholders' Equity | |||||
| Accounts payable | $ | 6,514 | $ | 8,359 | |
| Accrued expenses | 17,840 | 16,604 | |||
| Deferred service revenue | 8,078 | 8,427 | |||
| Deferred rent | 14,599 | 19 | |||
| Other liabilities | 1,915 | 3,345 | |||
| Financing derivative | 15 | 356 | |||
| Notes payable | 13,084 | 16,106 | |||
| Stockholders' equity | 115,860 | 84,668 | |||
| Total Liabilities and Stockholders' Equity | $ | 177,905 | $ | 137,884 | |
Contact: Trevin Rard 650.521.8450 [email protected]
